Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Published Online: 2021-08-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Aiwen Wu•Baoqing Jia•Changming Huang•Changsong Qi•Chen Yao•Chengxue Dang•Dan Wu•Fei Li•Gang Xiao•Guanbao Zhu•Guoli Li•Han Liang•Huanqiu Chen•Huimian Xu•Jiafu Ji•Jian Suo•Jian-Yu E•Jiren Yu•Leping Li•Li Chen•Lianhai Zhang•Lin Chen•Lin Shen•Ming Cui•Peiwu Yu•Xiangji Ying•Xiangqian Su•Xiaojiang Wu•Xiaotian Zhang•Xin Wang•Xinbao Wang•Yanbing Zhou•Yannan Yuan•Yanong Wang•Yian Du•Yihong Sun•Yingjiang Ye•Yingwei Xue•Yong Li•Yulong He•Yuxian Bai•Zhaode Bu•Zhiwei Zhou•Zhongtao Zhang•Ziyu Li
